Language
English
Publication Date
1-8-2026
Journal
American Journal of Epidemiology
DOI
10.1093/aje/kwaf176
PMID
40838594
PMCID
PMC12448673
PubMedCentral® Posted Date
9-20-2025
PubMedCentral® Full Text Version
Author MSS
Abstract
Negative control outcomes (NCOs) are useful tools for hidden bias detection, but empirical evidence validating NCOs for COVID-19 is lacking. To address this gap, we examined the blinded phase of the randomized, placebo-controlled Coronavirus Vaccine Efficacy (COVE; NCT04470427) trial of the mRNA-1273 COVID-19 vaccine. We confirmed that acute respiratory illness with a positive test for a non-SARS-CoV-2 respiratory pathogen on a multiplex PCR panel was a valid NCO for COVID-19, considering that it was unaffected by vaccination (vaccine efficacy, VE=3.3% (95% CI, −22.3–23.6)) yet strongly associated with COVID-19 (odds ratio=2.95 (95% CI, 2.00–4.24)). Subsequently, we leveraged non-SARS-CoV-2 infections to detect bias in time-varying VE estimates from COVE’s blinded and booster phases. Balanced incidence of non-SARS-CoV-2 infection between vaccinated and unvaccinated COVID-19-free risk sets suggested low selection bias in VE estimates of two-dose mRNA-1273 against COVID-19 during the blinded phase (VE=92.5% (95% CI, 88.8–94.9) 14 days post-dose-two, stable for 5 months). In COVE’s booster phase, higher non-SARS-CoV-2 incidence was observed after the single booster (intensity ratio, IR=2.38 (95% CI, 1.75–3.25) 14 days post-boost), suggesting that booster VE estimates may underestimate the true VE against COVID-19. Our findings demonstrate the potential of off-target infections for unraveling complex biases in COVID-19 vaccine studies.
Keywords
Adult, Female, Humans, Male, Middle Aged, 2019-nCoV Vaccine mRNA-1273, COVID-19, COVID-19 Vaccines, Follow-Up Studies, Respiratory Tract Infections, Vaccine Efficacy, Bias detection, unmeasured confounding, negative controls, depletion of susceptibles, waning vaccine efficacy
Published Open-Access
yes
Recommended Citation
Ashby, Ethan; Janes, Holly; Follmann, Dean; et al., "Validating and Leveraging Non-Sars-Cov-2 Respiratory Infection as a Negative Control Outcome in a Phase 3 COVID-19 Vaccine Trial With Extended Observational Follow-Up" (2026). Faculty, Staff and Students Publications. 8821.
https://digitalcommons.library.tmc.edu/baylor_docs/8821